Vertex Pharmaceuticals annual debt-to-assets ratio
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Vertex Pharmaceuticals Debt-to-Assets Ratio Growth & History (VRTX)
Vertex Pharmaceuticals's debt-to-assets ratio was 0.08 for fiscal 2025.
View full Vertex Pharmaceuticals company overviewVertex Pharmaceuticals annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.08 | 0.00 | +2.26% |
| 2024 | 2024-12-31 | 0.08 | 0.04 | +118.31% |
| 2023 | 2023-12-31 | 0.04 | −0.01 | −28.25% |
| 2022 | 2022-12-31 | 0.05 | −0.02 | −31.17% |
| 2021 | 2021-12-31 | 0.07 | −0.01 | −10.20% |
| 2020 | 2020-12-31 | 0.08 | −0.00 | −0.89% |
| 2019 | 2019-12-31 | 0.08 | −0.01 | −15.28% |
| 2018 | 2018-12-31 | 0.10 | 0.08 | +687.25% |
| 2017 | 2017-12-31 | 0.01 | −0.01 | −35.39% |
| 2016 | 2016-12-31 | 0.02 | −0.00 | −19.74% |
| 2015 | 2015-12-31 | 0.02 | −0.00 | −4.32% |
| 2014 | 2014-12-31 | 0.02 | −0.00 | −13.60% |
| 2013 | 2013-12-31 | 0.03 | 0.02 | +170.49% |
| 2012 | 2012-12-31 | 0.01 | 0.01 | — |
| 2011 | 2011-12-31 | 0.00 | — | — |
Vertex Pharmaceuticals quarterly debt-to-assets ratio
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.07 | 0.01 | +13.49% |
| Q1 2026 | 2026-03-31 | 0.08 | 0.00 | +4.07% |
| Q4 2025 | 2025-12-31 | 0.08 | 0.00 | +2.26% |
| Q3 2025 | 2025-09-30 | 0.07 | −0.01 | −7.49% |
| Q2 2025 | 2025-06-30 | 0.06 | 0.02 | +37.06% |
| Q1 2025 | 2025-03-31 | 0.07 | 0.04 | +138.99% |
| Q4 2024 | 2024-12-31 | 0.08 | 0.04 | +118.31% |
| Q3 2024 | 2024-09-30 | 0.08 | 0.05 | +132.72% |
| Q2 2024 | 2024-06-30 | 0.05 | 0.01 | +22.91% |
| Q1 2024 | 2024-03-31 | 0.03 | −0.01 | −27.49% |
| Q4 2023 | 2023-12-31 | 0.04 | −0.01 | −28.25% |
| Q3 2023 | 2023-09-30 | 0.03 | −0.02 | −30.56% |
| Q2 2023 | 2023-06-30 | 0.04 | −0.02 | −30.63% |
| Q1 2023 | 2023-03-31 | 0.04 | −0.02 | −32.04% |
| Q4 2022 | 2022-12-31 | 0.05 | −0.02 | −31.17% |
| Q3 2022 | 2022-09-30 | 0.05 | −0.02 | −28.96% |
| Q2 2022 | 2022-06-30 | 0.05 | −0.02 | −25.65% |
| Q1 2022 | 2022-03-31 | 0.06 | −0.01 | −17.50% |
| Q4 2021 | 2021-12-31 | 0.07 | −0.01 | −10.20% |
| Q3 2021 | 2021-09-30 | 0.07 | −0.00 | −3.65% |
| Q2 2021 | 2021-06-30 | 0.07 | 0.02 | +43.12% |
| Q1 2021 | 2021-03-31 | 0.07 | 0.01 | +23.80% |
| Q4 2020 | 2020-12-31 | 0.08 | −0.00 | −0.89% |
| Q3 2020 | 2020-09-30 | 0.07 | −0.01 | −16.60% |
| Q2 2020 | 2020-06-30 | 0.05 | −0.04 | −45.29% |
| Q1 2020 | 2020-03-31 | 0.06 | −0.04 | −41.22% |
| Q4 2019 | 2019-12-31 | 0.08 | −0.01 | −15.28% |
| Q3 2019 | 2019-09-30 | 0.09 | 0.08 | +1399.23% |
| Q2 2019 | 2019-06-30 | 0.09 | 0.09 | +1245.76% |
| Q1 2019 | 2019-03-31 | 0.10 | 0.09 | +1091.34% |
| Q4 2018 | 2018-12-31 | 0.10 | 0.08 | +687.25% |
| Q3 2018 | 2018-09-30 | 0.01 | −0.01 | −54.04% |
| Q2 2018 | 2018-06-30 | 0.01 | −0.01 | −47.61% |
| Q1 2018 | 2018-03-31 | 0.01 | −0.01 | −49.18% |
| Q4 2017 | 2017-12-31 | 0.01 | −0.01 | −35.39% |
| Q3 2017 | 2017-09-30 | 0.01 | −0.01 | −33.82% |
| Q2 2017 | 2017-06-30 | 0.01 | −0.01 | −34.77% |
| Q1 2017 | 2017-03-31 | 0.02 | −0.01 | −25.42% |
| Q4 2016 | 2016-12-31 | 0.02 | −0.00 | −19.74% |
| Q3 2016 | 2016-09-30 | 0.02 | −0.00 | −13.60% |
| Q2 2016 | 2016-06-30 | 0.02 | −0.00 | −15.15% |
| Q1 2016 | 2016-03-31 | 0.02 | −0.01 | −26.06% |
| Q4 2015 | 2015-12-31 | 0.02 | −0.00 | −4.32% |
| Q3 2015 | 2015-09-30 | 0.02 | −0.00 | −12.45% |
| Q2 2015 | 2015-06-30 | 0.02 | −0.01 | −21.73% |
| Q1 2015 | 2015-03-31 | 0.03 | −0.00 | −1.06% |
| Q4 2014 | 2014-12-31 | 0.02 | −0.00 | −13.60% |
| Q3 2014 | 2014-09-30 | 0.03 | 0.00 | +20.34% |
| Q2 2014 | 2014-06-30 | 0.03 | 0.02 | +103.93% |
| Q1 2014 | 2014-03-31 | 0.03 | 0.02 | +220.25% |
| Q4 2013 | 2013-12-31 | 0.03 | 0.02 | +170.49% |
| Q3 2013 | 2013-09-30 | 0.02 | 0.02 | — |
| Q2 2013 | 2013-06-30 | 0.01 | 0.01 | — |
| Q1 2013 | 2013-03-31 | 0.01 | 0.01 | — |
| Q4 2012 | 2012-12-31 | 0.01 | 0.01 | — |
| Q3 2012 | 2012-09-30 | 0.00 | −0.05 | — |
| Q2 2012 | 2012-06-30 | 0.00 | −0.06 | — |
| Q1 2012 | 2012-03-31 | 0.00 | −0.07 | — |
| Q4 2011 | 2011-12-31 | 0.00 | — | — |
| Q3 2011 | 2011-09-30 | 0.05 | — | — |
| Q2 2011 | 2011-06-30 | 0.06 | — | — |
| Q1 2011 | 2011-03-31 | 0.07 | — | — |
Vertex Pharmaceuticals debt-to-assets ratio trends
Over the last five fiscal years, Vertex Pharmaceuticals's debt-to-assets ratio decreased from 0.08 to 0.08, a change of −0.00. The latest reported quarter, Q2 2026, shows 0.07.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vertex Pharmaceuticals source filings ↗Community posts
Vertex adds detailed kidney-response data and launches patient-experience trial
Vertex ($VRTX) released additional Phase 3 RAINIER findings for povetacicept in IgA nephropathy. At week 36, 42.2% of treated participants achieved a urine protein-to-creatinine ratio below 0.5 grams per gram, compared with 6.2% receiving p ...
